Abstract
BackgroundThe symptoms of multiple sclerosis (MS) are caused by damage to myelin and nerve cells in the brain and spinal cord. Inflammation is tightly linked with neurodegeneration, and it is the accumulation of neurodegeneration that underlies increasing neurological disability in progressive MS. Determining pathological mechanisms at play in MS grey matter is therefore a key to our understanding of disease progression.MethodsWe analysed complement expression and activation by immunocytochemistry and in situ hybridisation in frozen or formalin-fixed paraffin-embedded post-mortem tissue blocks from 22 progressive MS cases and made comparisons to inflammatory central nervous system disease and non-neurological disease controls.ResultsExpression of the transcript for C1qA was noted in neurons and the activation fragment and opsonin C3b-labelled neurons and glia in the MS cortical and deep grey matter. The density of immunostained cells positive for the classical complement pathway protein C1q and the alternative complement pathway activation fragment Bb was significantly increased in cortical grey matter lesions in comparison to control grey matter. The number of cells immunostained for the membrane attack complex was elevated in cortical lesions, indicating complement activation to completion. The numbers of classical (C1-inhibitor) and alternative (factor H) pathway regulator-positive cells were unchanged between MS and controls, whilst complement anaphylatoxin receptor-bearing microglia in the MS cortex were found closely apposed to cortical neurons. Complement immunopositive neurons displayed an altered nuclear morphology, indicative of cell stress/damage, supporting our finding of significant neurodegeneration in cortical grey matter lesions.ConclusionsComplement is activated in the MS cortical grey matter lesions in areas of elevated numbers of complement receptor-positive microglia and suggests that complement over-activation may contribute to the worsening pathology that underlies the irreversible progression of MS.Electronic supplementary materialThe online version of this article (doi:10.1186/s12974-016-0611-x) contains supplementary material, which is available to authorized users.
Highlights
The symptoms of multiple sclerosis (MS) are caused by damage to myelin and nerve cells in the brain and spinal cord
We have examined the localisation of complement recognition molecules (C1q), activation products (C3b, Bb, membrane attack complex (MAC)), regulators and receptors (C3aR, C5aR and complement receptor 3/ CD11b) for the first time in order to better understand the immune mechanisms of MS cortical grey matter pathology relevant to disease progression
There was an increase in the proportion of C3b+ cells with a neuronal morphology out of the total number of C3b+ quantified cells in MS cortical GM (normal appearing grey matter (GMN) and Grey matter lesions (GML)), in comparison to nonneurological control samples (Fig. 1h)
Summary
The symptoms of multiple sclerosis (MS) are caused by damage to myelin and nerve cells in the brain and spinal cord. Determining pathological mechanisms at play in MS grey matter is a key to our understanding of disease progression. Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of young adults. Complement is activated through the classical, lectin and alternative pathways that generate anaphylatoxins C3a and C5a and opsonins, including C3b [11, 12]. Host cells express an array of complement regulatory proteins (Cregs) that, for example, inhibit C3cleaving enzymes (factor H), prevent C1q assembly with C1r, s and initiation of the classical pathway (C1inhibitor) or block assembly of the MAC (clusterin) [13]. Intrathecal and blood-borne levels of complement proteins mirror the MS disease profile [14,15,16,17], but we need to know more about the role of complement in pathogenesis
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.